Biocon Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved the financial results, which include standalone and consolidated figures prepared as per Indian Accounting Standards. The company also noted changes in its senior management personnel, including the resignation of its Chief Technology Officer and the appointment of a new CTO. The financial results were reviewed by statutory auditors.
Biocon Announces Q2 FY27 Financial Results and Senior Management Changes
Biocon Limited has officially announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company’s Board of Directors, at a meeting held on November 04, 2026, approved these results, which encompass both standalone and consolidated financial statements prepared in accordance with Indian Accounting Standards (Ind-AS).
Key Financial Highlights
The unaudited financial results for the period indicate the company’s performance, with detailed standalone and consolidated figures provided for the quarter and half-year ending September 30, 2026. These results were subjected to a limited review by the company’s statutory auditors, who provided an unqualified report.
Senior Management Transitions
In addition to the financial updates, Biocon Limited also disclosed significant changes within its senior management team. The Board noted the resignation of Dr. Mandar Shrikant Ghatnekar from his position as Chief Technology Officer (Senior Management Personnel), effective the close of business hours on December 31, 2026. Following this, the Board approved the appointment of Mr. Mukesh Rathi as the new Chief Technology Officer (Senior Management Personnel), effective January 01, 2027. Details pertaining to these changes, as required by SEBI Listing Regulations, are provided in Annexure I, including brief profiles and effective dates.
Additional Information
The Board meeting commenced at 11:20 AM and concluded at 01:10 PM on November 04, 2026. Further details about the financial results and management changes are available on the company’s website, www.biocon.com.
Source: BSE
